每周使用脂质体两性霉素B对慢性肺曲霉病进行初始治疗：来自乌干达的一例病例报告。
Primary treatment of chronic pulmonary aspergillosis with weekly liposomal amphotericin B: A case report from Uganda.
作者信息
Kibone Winnie, Bongomin Felix, Denning David W, Meya David B
机构信息
Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda.
Department of Internal Medicine, Mulago National Referral Hospital, Kampala, Uganda.
出版信息
Med Mycol Case Rep. 2024 Aug 27;46:100666. doi: 10.1016/j.mmcr.2024.100666. eCollection 2024 Dec.
Chronic pulmonary aspergillosis (CPA) treatment in Africa remains unexplored. We present a 23-year-old Ugandan male, previously treated thrice for pulmonary tuberculosis, developing CPA. Imaging showed lung fibrosis, bronchiectasis, and a fungal ball. He received weekly 600mg (10mg/kg) of liposomal amphotericin B for six weeks, leading to marked clinical improvement. Weekly liposomal amphotericin B may be a viable treatment option for CPA in resource-limited settings.
非洲慢性肺曲霉病（CPA）的治疗仍未得到充分探索。我们报告一名23岁的乌干达男性，曾三次接受肺结核治疗，后来患上了CPA。影像学检查显示肺部纤维化、支气管扩张和真菌球。他接受了为期六周的每周一次600毫克（10毫克/千克）的脂质体两性霉素B治疗，临床症状有显著改善。在资源有限的环境中，每周使用脂质体两性霉素B可能是治疗CPA的一个可行选择。
Zotero 插件